Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$5.6MCash on Hand
11.8mo Cash Runway
Follow CDIO by emailGet an email when CDIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CDIO, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 18, 2026 ·
Shareholder vote Shareholders elected seven directors, approved a proposal allowing share issuances of 20% or more of outstanding common stock in non-public transactions, and ratified Prager Metis CPA's LLC as auditor for fiscal 2026. About 60.25% of eligible shares were represented. Form 8-K · SEC filing
Aug 20, 2026 ·
Management will begin using an August 2026 investor presentation with existing and prospective investors, effective August 20, 2026. The presentation is also posted on the company's website. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2022 · N/A · Results Expected · Assessment of Lesion-Associated Myocardial Ischemia Based on Fusion Coronary CT Imaging Registry primary completion date, not a results date
Jul 2021 · N/A · Results Expected · The Assessment Of Myocardial Viability Based On CTA/MRI Hybrid Models Registry primary completion date, not a results date
Mar 2021 · N/A · Results Expected · Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease Registry primary completion date, not a results date
Mar 2021 · N/A · Results Expected · Inflammation-mediated Coronary Plaque Vulnerability, Myocardial Viability and Ventricular Remodeling Registry primary completion date, not a results date
Feb 2021 · N/A · Results Expected · Inflammation, Fibrosis and Risk of Recurrence After Atrial Fibrillation Ablation Registry primary completion date, not a results date
Jan 2021 · N/A · Results Expected · Periodontal Disease, Inflammation and Acute Coronary Syndromes Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CDIO holds $5.6M in cash and short-term investments and burns about $1.4M/quarter from operations,
an estimated runway of 11.8 months at that rate (BioRadar estimate, not company guidance).
Share count 2,959,469 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CDIO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CDIO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.